Bristol Myers Squibb emphasizes pipeline strength and later-stage partnership focus amid patent cliff concerns

Bristol Myers Squibb used its latest earnings call to outline how it plans to address an upcoming patent cliff that threatens revenue from several key products.

Executives said the company is relying on its current pipeline, including late-stage candidates, to sustain growth and is actively seeking business-development opportunities such as acquisitions or collaborations to bolster its portfolio.

The focus on later-stage deals reflects a strategy to diversify risk while the firm continues to invest in R&D, signaling confidence that its pipeline can offset the impact of expiring patents.